| Hollis-Eden News (2003-2004) |
 |
| Monday, September 29, 2008 |
| Hollis-Eden Pharmaceuticals Presents Additional Positive Findings for APOPTONE (HE3235) in Preclinical Models of Castration-Resistant Prostate Cancer Posted 8:09 AM PST |
| |
| Thursday, September 25, 2008 |
| Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistant Subjects Posted 7:53 AM PST |
| |
| Friday, September 12, 2008 |
| Hollis-Eden Pharmaceuticals Reports Update on Autoimmunity Program with TRIOLEX (HE3286) at International Autoimmunity Meeting 6th International Congress on Autoimmunity Posted 6:28 AM PST |
| |
| Thursday, August 7, 2008 |
| Hollis-Eden Pharmaceuticals Reports on Progress in Drug Development Programs Posted 9:06 AM PST |
| |
| Tuesday, August 5, 2008 |
| Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with TRIOLEX (HE3286) in Rheumatoid Arthritis Patients Posted 6:54 AM PST |
| |
| Wednesday, July 30, 2008 |
| Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial with APOPTONE (HE3235) in Late-Stage Prostate Cancer Patients Posted 6:04 AM PST |
| |
| Wednesday, July 16, 2008 |
| Hollis-Eden Pharmaceuticals Commences Phase II Clinical Trial with TRIOLEX (HE3286) in Type-2 Diabetes Patients; Expands Sites to Accelerate Enrollment Posted 5:51 AM PST |
| |
| Monday, June 9, 2008 |
| Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with TRIOLEX Supporting Anti-Inflammatory Approach to Treating Type 2 Diabetes Posted 6:27 AM PST |
| |
| Monday, May 12, 2008 |
| Hollis-Eden Pharmaceuticals to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference Posted 6:04 AM PST |
| |
| Monday, April 14, 2008 |
| Hollis-Eden Pharmaceuticals Presents Positive Data with APOPTONE in Preclinical Bone Model of Late-Stage Prostate Cancer Posted 4:13 PM PST |
| |
| Tuesday, March 18, 2008 |
| Hollis-Eden Pharmaceuticals Reports Positive Preliminary Data from Ongoing Phase I/II Clinical Trial with TRIOLEX in Obese Insulin Resistant Subjects Posted 6:47 AM PST |
| |
| Tuesday, March 11, 2008 |
| Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Fourth Quarter 2007 Financial Results and Drug Development Programs Posted 7:48 AM PST |
| |
| Tuesday, February 19, 2008 |
| Hollis-Eden Pharmaceuticals Announces Filing of IND with APOPTONE in Hormone Sensitive Cancers to Commence Phase I/II Clinical Trial in Late-Stage Prostate Cancer Posted 6:43 AM PST |
| |
| Friday, February 8, 2008 |
| Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial in Ulcerative Colitis with Novel Oral Anti-Inflammatory Drug Candidate TRIOLEX Posted 7:39 AM PST |
| |
| Tuesday, February 5, 2008 |
| Hollis-Eden Pharmaceuticals Presents Additional Data Demonstrating Activity of APOPTONE in Inducing Cancer Cell Death Findings Delivered in Oral Presentation at 19th International Congress on Anti-Cancer Agents Posted 7:50 AM PST |
| |
| Monday, February 4, 2008 |
| Hollis-Eden Pharmaceuticals to Present at 2008 BIO CEO and Investor Conference BIO CEO & Investor Conference 2008 Posted 7:45 AM PST |
| |
| Monday, December 3, 2007 |
| Hollis-Eden Pharmaceuticals to Present at the New York Society Of Security Analysts Biotech & Specialty Pharma Conference Posted 7:40 AM PST |
| |
| Monday, November 19, 2007 |
| Hollis-Eden Pharmaceuticals Presents Data Demonstrating TRIOLEX™ Provides Benefit in Additional Animal Model of Rheumatoid Arthritis Posted 7:31 AM PST |
| |
| Monday, November 12, 2007 |
| Hollis-Eden Pharmaceuticals Presents Data on APOPTONE™ and Potential Role of Adrenal Steroid Hormones for the Treatment of Cancer Posted 8:31 AM PST |
| |
| Friday, November 2, 2007 |
| Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Program Posted 6:34 AM PST |
| |
| Monday, October 29, 2007 |
| Hollis-Eden Pharmaceuticals Announces Conference Call and Webcast on Third Quarter 2007 Financial Results and Drug Development Programs Posted 6:48 AM PST |
| |
| Tuesday, October 16, 2007 |
| Hollis-Eden Pharmaceuticals Commencing Phase I/II Clinical Trial with TRIOLEX (HE3286) in Obese, Insulin Resistant Volunteers Posted 4:17 AM PST |
| |
| Tuesday, October 9, 2007 |
| Hollis-Eden Pharmaceuticals Presents Positive Data Demonstrating HE3286 Provides Benefit in Animal Model of Ulcerative Colitis Posted 3:47 AM PST |
| |
| Friday, October 5, 2007 |
| Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235 in Model of Hormone Independent Prostate Cancer Posted 4:19 AM PST |
| |
| Monday, September 17, 2007 |
| Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I/II Clinical Trials with HE3286 in Diseases of Inflammation Posted 6:09 AM PST |
| |
| Wednesday, September 12, 2007 |
| Hollis-Eden Pharmaceuticals Reports on Anti-Inflammatory Activity with HE3286 in Models of Diseases of Inflammation Posted 6:45 AM PST |
| |
| Friday, September 7, 2007 |
| Hollis-Eden Pharmaceuticals Presents HE3235 Update at ASCO Breast Cancer Symposium Posted 5:56 AM PST |
| |
| Friday, August 3, 2007 |
| Hollis-Eden Pharmaceuticals Reports on Progress in Drug Development Programs; Announces Second Quarter 2007 Financial Results Posted 8:05 AM PST |
| |
| Thursday, August 2, 2007 |
| SAN DIEGO--- Hollis-Eden Pharmaceuticals Names Scott M. Freeman, M.D., Chief Medical Officer Posted 9:02 AM PST |
| |
| Monday, July 16, 2007 |
| Hollis-Eden Pharmaceuticals Reports Initial Results in Phase I Clinical Trial of HE3286 as New Type II Diabetes Treatment Posted 7:59 AM PST |
| |
| Tuesday, May 22, 2007 |
| SAN DIEGO--- Mpex Pharmaceuticals Names Daniel D. Burgess as Chief Executive Officer Posted 9:04 AM PST |
| |
| Friday, May 4, 2007 |
| Hollis-Eden Pharmaceuticals Announces Financial Results for First Quarter 2007 Posted 4:29 PM PST |
| |
| Tuesday, May 1, 2007 |
| Hollis-Eden Pharmaceuticals Cleared by FDA to Initiate Phase I Clinical Trial with HE3286 in Treating Metabolic Disorders Posted 8:33 AM PST |
| |
| Friday, April 27, 2007 |
| Hollis-Eden Pharmaceuticals Announces Reorganization; Company to Focus Core Technology on Metabolic Disorders, Autoimmunity and Cancer Posted 6:52 AM PST |
| |
| Thursday, March 29, 2007 |
| Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I Clinical Trial with Next-Generation Drug Candidate HE3286 in Metabolic Disorders Posted 6:48 AM PST |
| |
| Friday, March 16, 2007 |
| Hollis-Eden Pharmaceuticals Announces Fourth Quarter and Year-End 2006 Financial Results Posted 5:49 AM PST |
| |
| Thursday, March 8, 2007 |
| Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP by Department of Health and Human Services Posted 7:28 AM PST |
| |
| Monday, February 26, 2007 |
| Hollis-Eden Pharmaceuticals Reports Publication of Results Demonstrating the Ability of NEUMUNE to Increase Survival in a Primate Model of Lethal Radiation Injury Posted 7:27 AM PST |
| |
| Friday, February 2, 2007 |
| Hollis-Eden Pharmaceuticals Presents Positive Data with HE3286 in Preclinical Model of Established Rheumatoid Arthritis Posted 8:02 AM PST |
| |
| Thursday, February 1, 2007 |
| Hollis-Eden Pharmaceuticals Provides Update on Negotiations for BioShield Procurement Contract for NEUMUNE as a Treatment for Acute Radiation Syndrome Posted 8:17 AM PST |
| |
| Tuesday, January 16, 2007 |
| Hollis-Eden Pharmaceuticals Presents Data Demonstrating Discovery of an Endogenous Hormone Potentially Central to Glucose Metabolism Posted 8:11 AM PST |
| |
| Wednesday, November 8, 2006 |
| SAN DIEGO--- Hollis-Eden Pharmaceuticals to Raise $26.0 Million Through Sale of Common Stock and Warrants Posted 7:42 AM PST |
| |
| Friday, November 3, 2006 |
| Hollis-Eden Pharmaceuticals Provides Update on Final Stages of Negotiations for BioShield Procurement Contract Posted 8:17 AM PST |
| |
| Hollis-Eden Pharmaceuticals Announces Third Quarter 2006 Financial Results Posted 7:45 AM PST |
| |
| Hollis-Eden Pharmaceuticals Provides Update on Final Stages of Negotiations for BioShield Procurement Contract Posted 6:52 AM PST |
| |
| Wednesday, September 27, 2006 |
| Hollis-Eden Pharmaceuticals Grants Extension of Offer to Department of Health and Human Services for Acute Radiation Syndrome Candidate Posted 6:06 AM PST |
| |
| Friday, August 4, 2006 |
| Hollis-Eden Pharmaceuticals Announces Second Quarter 2006 Financial Results Posted 6:35 AM PST |
| |
| Monday, July 31, 2006 |
| Hollis-Eden Pharmaceuticals Announces Second Quarter 2006 Conference Call and Investor Conference Webcasts Posted 4:52 AM PST |
| |
| Friday, June 16, 2006 |
| Hollis-Eden Pharmaceuticals Files Shelf Registration Statement Posted 3:09 PM PST |
| |
| Thursday, June 8, 2006 |
| Hollis-Eden Pharmaceuticals Announces FDA Clearance to Commence Human Clinical Study with NEUMUNE in Patients at Risk of Healthcare-Associated Infections Posted 6:29 AM PST |
| |
| Wednesday, May 10, 2006 |
| Hollis-Eden Pharmaceuticals Announces Financial Results for First Quarter 2006 Posted 6:23 AM PST |
| |
| Thursday, May 4, 2006 |
| Hollis-Eden Pharmaceuticals Announces First Quarter 2006 Conference Call and Investor Conference Webcasts Posted 6:45 AM PST |
| |
| Wednesday, May 3, 2006 |
| Hollis-Eden Announces Filing of IND for Phase I Clinical Trials with NEUMUNE in Patients at Risk of Hospital-Acquired Infections Posted 8:17 AM PST |
| |
| Thursday, March 16, 2006 |
| Hollis-Eden Pharmaceuticals Announces Fourth Quarter and Year-End 2005 Financial Results Posted 8:42 AM PST |
| |
| Friday, February 24, 2006 |
| Hollis-Eden Pharmaceuticals Submits Proposal in Response to Department of Health and Human Services Solicitation for Acute Radiation Syndrome (ARS) Therapy Posted 7:54 AM PST |
| |
